Tourbillon Capital Partners’s Sarepta Therapeutics SRPT Stock Holding History

Tourbillon Capital Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-200,000	Closed	-$14.8M	–	96
2018 Q1	$14.8M	Sell	200,000 -900,000	-82%	-$60M	0.59%	47
2017 Q4	$61.2M	Sell	1,100,000 -370,400	-25%	-$19.6M	2.26%	15
2017 Q3	$66.7M	Buy	1,470,400 +1,139,000	+344%	+$45.5M	1.62%	21
2017 Q2	$11.2M	Sell	331,400 -22,300	-6%	-$726K	0.22%	60
2017 Q1	$10.5M	Sell	353,700 -1,111,700	-76%	-$34.4M	0.27%	50
2016 Q4	$40.2M	Buy	1,465,400 +1,165,400	+388%	+$46.8M	0.77%	34
2016 Q3	$18.4M	Buy	+300,000	New	+$9.07M	0.38%	55
2016 Q2	–	Sell	-115,000	Closed	-$2.25M	–	80
2016 Q1	$2.25M	Buy	+115,000	New	+$2.01M	0.05%	62

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Tourbillon Capital Partners's SRPT Position: Q2 2018 in Review

Tourbillon Capital Partners sold out of Sarepta Therapeutics (SRPT) in Q2 2018, closing a stake of 758,413 shares — an estimated $56.2M sold.

Tourbillon Capital Partners first reported a position in SRPT in Q1 2016 and held it in 8 quarters. The position peaked at $105M in Q3 2016. 318 funds tracked by Wall St. Rank hold SRPT as of Q2 2018.

Tourbillon Capital Partners reported no remaining Sarepta Therapeutics position as of Q2 2018 after selling out during the quarter.
Tourbillon Capital Partners sold 758,413 Sarepta Therapeutics shares in Q2 2018, an estimated $56.2M.
Tourbillon Capital Partners first reported a position in Sarepta Therapeutics in Q1 2016 and held it in 8 quarters.
Tourbillon Capital Partners's Sarepta Therapeutics position peaked at $105M in Q3 2016.
318 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2018.

Based on Tourbillon Capital Partners's 13F filing for Q2 2018, filed 14 Aug 2018.